

Nanoform partners with CBC to bring best-in-class nanomedicine technology to Japan

15 April 2024 | News

Nanoform technology has been effective in several in vitro and in vivo studies

Nanoform Finland Plc has announced a strategic partnership whereby CBC Co. will utilise its extensive experience in the Japanese pharmaceutical industry to identify opportunities for Nanoform's cutting-edge nanomedicine engineering technologies.

Nanoformed medicines have been shown to overcome innovators' drug bioavailability issues and reduce dose size and pill burden to improve patient-acceptance, both for new drugs and reformulations of existing products.

"This strategic partnership with CBC represents a significant milestone in our ongoing effort to bring our cutting-edge nanotechnology to enable improved medicines for patients around the world. Japan is a key country for innovative drug development, and we are excited to work with a partner that shares our commitment to bringing meaningful innovation to patients faster," said Christian Jones, Chief Commercial Officer at Nanoform.

Shinya Miyairi, Managing Executive Officer at CBC said, "We believe that Nanoform's technologies represent a great fit for the Japanese market where the ability to provide medicines with higher bioavailability and fewer and smaller doses are important for success."

Nanoform technology has been effective in several in vitro and in vivo studies across multiple routes of administration including oral, inhaled, ophthalmic and injectables, and across multiple molecule types such as enzalutamide and many other molecules.

The partnership commences immediately, and the companies have planned several joint activities to introduce their collaboration, including representation of Nanoform by CBC at CPHI Japan, which takes place at Tokyo Big Sight, Tokyo, from April 17-19, 2024.